AlloVir (ALVR) shareholders have approved the company's proposed merger with Kalaris Therapeutics at a special meeting held Wednesday, the companies said the same day.
The merger is expected to close "as soon as practicable" and the combined company will be renamed as Kalaris Therapeutics, with "KLRS" as its updated trading symbol on Nasdaq.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.